Headache News and Research

Latest Headache News and Research

Botox effect modest in migraine prevention: Study

Botox injections have been used in prevention of migraines but new research shows that its effect is only modest. Among chronic sufferers who had at least 15 migraines a month, the treatment prevented, on average, about two headaches a month. Botox was no more effective than some of the most widely prescribed drugs used for migraines when the treatments were compared.

25 Apr 2012

South African model for concussion management

Jon Patricios, MMBCh, MMed Sci, will be presenting "Mandela's Mantra: A South African Model for Concussion Management" at the 21st American Medical Society for Sports Medicine Annual Meeting in Atlanta, GA on Tuesday, April 24.

25 Apr 2012

Preventive treatments can reduce migraine attacks

Research shows that many treatments can help prevent migraine in certain people, yet few people with migraine who are candidates for these preventive treatments actually use them, according to new guidelines issued by the American Academy of Neurology.

24 Apr 2012

Migraine prevention guidelines released

The latest migraine prevention guidelines will be presented at the American Academy of Neurology's annual meeting in New Orleans and published simultaneously in the journal Neurology.

24 Apr 2012

Botox injections may improve frequency of chronic daily and migraine headaches

Although botulinum toxin A injections are U.S. Food and Drug Administration approved for preventive treatment for chronic migraines, a review and analysis of previous studies finds a small to modest benefit for patients with chronic migraine headaches and chronic daily headaches, although botox injections were not associated with greater benefit than placebo for preventing episodic migraine or chronic tension-type headaches, according to an article in the April 25 issue of JAMA.

24 Apr 2012

‘Brain freeze’ provides clue to migraine cause and therapy

According to latest reports by researchers the headache that is caused by eating something cold like an ice cream, may be caused by a sudden change in brain blood flow. The U.S. team of researchers add that this study may show targets to treat other, more troubling forms of headache such as migraine.

23 Apr 2012

Brain injury in amateur boxing similar to Alzheimer´s

Olympic boxers can exhibit changes in brain fluids after bouts, which indicates nerve cell damage. This is shown in a study of 30 top-level Swedish boxers that was conducted at the Sahlgrenska Academy at the University of Gothenburg, Sweden, in collaboration with the Swedish Boxing Federation, published in PLoS ONE.

23 Apr 2012

Brain freeze may share common mechanism with other types of headaches

'Brain freeze' is a nearly universal experience—almost everyone has felt the near-instantaneous headache brought on by a bite of ice cream or slurp of ice-cold soda on the upper palate. However, scientists are still at a loss to explain this phenomenon. Since migraine sufferers are more likely to experience brain freeze than people who don't have this often-debilitating condition, brain freeze may share a common mechanism with other types of headaches, including those brought on by the trauma of blast-related combat injuries in soldiers.

23 Apr 2012

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.

20 Apr 2012

Interferon beta-1a shows promise against MS

People who received injections of the multiple sclerosis (MS) drug interferon beta-1a soon after their first signs of possible MS were less likely to progress to clinically definite MS than people who switched to interferon beta-1a from placebo, according to new phase three results of the three-year REFLEXION clinical trial that will be presented as part of the Emerging Science program at the American Academy of Neurology's 64th Annual Meeting in New Orleans, April 21 to April 28, 2012.

20 Apr 2012

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.

20 Apr 2012

Report: More patients turning to social media for medical advice

According to a new report, a third of consumers use social media to seek medical information, leading some to say that providers and insurers should utilize the media more to better interact with patients about their conditions.

19 Apr 2012

Biogen Idec launches FAMPYRA in Canada

Today, Biogen Idec Canada announces that FAMPYRA (fampridine sustained release tablets or fampridine SR) is now available for prescription for patients living with multiple sclerosis (MS) in Canada.

12 Apr 2012

New 4th Edition of Practical Neurology for clinicians, residents and fellows

The new 4th Edition of Practical Neurology, the respected "real-life" guide to diagnosing and managing neurologic disorders, has been completely rewritten to known neurologist and chair of the Department of Neurology of Loyola University Chicago Stritch School of Medicine.

11 Apr 2012

Siemens announces integrated imaging solution for detection of amyloid plaques

Siemens Healthcare is the first company worldwide to announce a complete integrated diagnostic imaging solution proposed for the detection of amyloid plaques — one of the necessary pathological features of Alzheimer's disease— in the living brain.

From Siemens Healthineers 11 Apr 2012

Amgen enters agreement to acquire KAI Pharmaceuticals

Amgen and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco.

11 Apr 2012

Avid Radiopharmaceuticals receives FDA approval for Amyvid to treat AD

The U.S. Food and Drug Administration today approved Amyvid (Florbetapir F 18 Injection) a drug for Positron Emission Tomography (PET) imaging of the brain in adults who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.

11 Apr 2012

NIH awards Winston SBIR grant to develop Civamide for postherpetic neuralgia of TN

Winston Pharmaceuticals, Inc.,, announced that the National Institutes of Health has awarded Winston a grant under the Small Business Innovation Research program supporting the development of Civamide, a proprietary TRPV-1 receptor modulator, for the treatment of postherpetic neuralgia of the trigeminal nerve.

9 Apr 2012

Lilly, Avid receive FDA approval for Amyvid to treat Alzheimer's

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.

7 Apr 2012

Purdue Pharma launches Intermezzo for middle-of-the-night insomnia

Purdue Pharma L.P. announced today that Intermezzo (zolpidem tartrate) sublingual tablet CIV is now available in 1.75 mg and 3.5 mg dosage strengths by prescription in retail pharmacies nationwide.

6 Apr 2012